<DOC>
	<DOCNO>NCT01176552</DOCNO>
	<brief_summary>This prospective study assess toxicity potential efficacy granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , interferon ( IFN ) alpha interleukin-2 ( IL-2 ) postoperatively patient high-risk renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>Granulocyte-macrophage Colony-stimulating Factor , Interferon Interleukin-2 Adjuvant Treatment Renal Cancer</brief_title>
	<detailed_description>Patients high-risk RCC dismal prognosis . To date , effective adjuvant therapy exist patient category . We suggest combination granulocyte-macrophage colony-stimulating factor ( GM-CSF ) , interferon alpha ( IFN ) interleukin-2 ( IL-2 ) stimulate immune system dendritic cell till cytotoxic T-lymphocytes step step eliminate residuary tumor cell . This prospective , non-randomized , phase II trial assess low-dose GM-CSF , IFN IL-2 postoperatively patient high-risk renal cell carcinoma .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>completely resect advanced highrisk RCC T3bc , T4 , N12 , M1 disease resect evidence disease ( AJCCTNM , 2002 ) Patients must recover effect surgery , must excellent performance status ( Eastern Cooperative Oncology Group performance status 0 1 ) ; adequate organ function define WBC count 4,000/µL , platelet count 100,000/µL , hemoglobin 10 g/dL , serum creatinine 1.5 mg/dL creatinine clearance 60 mL/min , direct bilirubin 1.5 mg/dL ; force expiratory volume 1 second 2.0 L 75 % predict height age preenrollment pulmonary function test age 18 year old history evidence cardiac disease ECG autoimmunity prior systemic treatment RCC history invasive malignancy past 5 year human immunodeficiency virus positivity positive pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Kidney Cancer</keyword>
	<keyword>Renal cell carcinoma</keyword>
	<keyword>High risk</keyword>
	<keyword>Adjuvant therapy</keyword>
</DOC>